{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:25:29Z","timestamp":1761596729440},"reference-count":53,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,9,23]],"date-time":"2008-09-23T00:00:00Z","timestamp":1222128000000},"content-version":"vor","delay-in-days":3859,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[1998,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Leflunomide is a new anti\u2010inflammatory and immunomodulating agent which is showing promise in several immune disorders, especially rheumatoid arthritis. Its activity profile suggests it may be of use in modulating allergic sensitization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the effectiveness of leflunomide in preventing the development of allergic sensitization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Fifty\u2010three brown Norway rats were sensitized by intraperitoneal injection of ovalbumin and adjuvant (ricin) on day 0. To determine the ability of leflunomide to inhibit primary allergic sensitization six rats were treated with A77 1726, the active metabolite of leflunomide, from day 0 through day 5, six were treated from day 5 through day 10, and nine rats acted as controls. On day 14, ovalbumin\u2010specific serum antibody levels and the magnitude of the early\u2010phase airway response (EAR) after inhalation allergen challenge were assessed. To determine the ability of acute topical treatment with leflunomide to inhibit mast cell degranulation, three groups of five animals received either vehicle, 100\u2003\u03bcg A77 1726, or 1000\u2003\u03bcg A77 1726 60\u2003min prior to aerosol allergen challenge. To determine the effects of leflunomide treatment <jats:italic>in vivo<\/jats:italic> on mast cell function <jats:italic>in vitro<\/jats:italic>, mast cells were obtained by bronchoalveolar lavage from 17 rats (nine treated with leflunomide and eight controls). Allergen\u2010specific and non\u2010specific degranulation (48\/80 induced) were studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the leflunomide treated rats both ovalbumin\u2010specific IgE and IgG levels were significantly reduced, and the increases in lung resistance and lung elastance were essentially abolished, compared to those of the control group. Non significant differences were found in any of the parameters between the two leflunomide treated groups. Topical pre\u2010treatment with leflunomide did not prevent the allergen\u2010induced EAR. Treatment with leflunomide <jats:italic>in vivo<\/jats:italic> prevented allergen\u2010induced mast cell degranulation <jats:italic>in vitro<\/jats:italic> because the mast cells lacked IgE on their surface. Non allergen\u2010specific degranulation was normal and allergen\u2010induced degranulation could be restored by passive sensitization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These data suggests that leflunomide can prevent primary allergic sensitization and prevent allergen\u2010induced EAR by inhibiting production of allergen\u2010specific IgE antibodies. Further studies in atopic conditions are warranted.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2222.1998.00240.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T09:31:13Z","timestamp":1047375073000},"page":"376-384","source":"Crossref","is-referenced-by-count":13,"title":["Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma"],"prefix":"10.1111","volume":"28","author":[{"family":"Eber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Mcmenamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Sly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,9,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1183\/09031936.93.05050601","volume":"5","year":"1992","journal-title":"Eur Respir J"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.52.1.1"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.18.6880"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(89)90031-6"},{"key":"e_1_2_6_6_2","first-page":"986","article-title":"Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provacation in asthma","volume":"132","author":"Howarth PH","year":"1985","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(87)90204-1"},{"key":"e_1_2_6_8_2","unstructured":"BartlettRR CampionG MusikicP. et al. Leflunomide: A novel immunomodulating drug. In Nonsteroidal anti\u2010inflammatory drugs. Mechanisms and clinical uses. AJ Lewis Furst DE eds. New York Basel Hong Kong: Marcel Dekker Inc. 1989:34966."},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01971235"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(89)90114-8"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0162-3109(92)90034-A"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00192310"},{"key":"e_1_2_6_13_2","first-page":"1083","article-title":"Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent","volume":"23","author":"K\u00fcchle CC","year":"1991","journal-title":"Transplant Proc"},{"key":"e_1_2_6_14_2","first-page":"718","article-title":"Suppression of natural xenophile antibodies with the novel immunomodulating drug leflunomide","volume":"24","author":"Ulrichs K","year":"1992","journal-title":"Transplant Proc"},{"key":"e_1_2_6_15_2","first-page":"763","article-title":"Prolongation of allogenetic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxaszol derivative","volume":"25","author":"Schorlemmer HU","year":"1993","journal-title":"Transplant Proc"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199404270-00015"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780381111"},{"key":"e_1_2_6_18_2","unstructured":"BartlettRR MattarT WeithmannULeflunomide (HWA 486): a novel immunorestoring drug. In: Lewis AJ Doherty NS Ackerman NR eds. Therapeutic approaches to inflammatory diseases. New York: Elsevier Science Publishing1989;21528."},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1183\/09031936.93.04101275","article-title":"Non\u2010invasive determination of alveolar pressure during mechanical ventilation","volume":"4","author":"Nicolai T","year":"1991","journal-title":"Eur Respir J"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.3.8087349"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)70305-1"},{"key":"e_1_2_6_22_2","first-page":"635","article-title":"Induction of IgE\u2010isotype specific tolerance by passive stimulation of the respiratory mucosa","volume":"50","author":"Sedgwick JD","year":"1983","journal-title":"Immunology"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00517983"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/icb.1982.63"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/137.5.1033"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(91)90253-K"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/147.1.104"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000231663"},{"key":"e_1_2_6_29_2","first-page":"151","article-title":"The influence of antigen dose on IgE production in different strains","volume":"36","author":"Pauwels R","year":"1979","journal-title":"Immunology"},{"key":"e_1_2_6_30_2","first-page":"256","article-title":"IgE production, antigen\u2010induced airway inflammation and airway hyperreactivity in the Brown Norway rat: the effects of ricin","volume":"85","author":"Underwood SL","year":"1995","journal-title":"Immunology"},{"key":"e_1_2_6_31_2","first-page":"513","article-title":"Elimination of IgE regulatory rat CD8+ T cells in vivo deferentially modulates interleukin\u20104 and interferon\u2010gamma but not interleukin\u20102 production by splenic T cells","volume":"78","author":"Diass\u2010Sacnchez D","year":"1993","journal-title":"Immunology"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/142.2.434"},{"key":"e_1_2_6_33_2","first-page":"62","article-title":"The requirement for polymorphonuclear leukocytes in the late asthmatic response and heightened airways reactivity in an animal model","volume":"134","author":"Murphy KR","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_6_34_2","first-page":"364","article-title":"Characterization of Fc receptor for IgE on human alveolar macrophages","volume":"49","author":"Melewicz FM","year":"1982","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198106043042307"},{"key":"e_1_2_6_36_2","unstructured":"LaiCKW&HolgateST. The mast cell in asthma. In: Kay AB ed. Clinical immunology and allergy: the allergic basis of asthma. London: Balliere Tindall1988;3765."},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.5.1381"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.10.5.8179909"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.2_Pt_1.332"},{"key":"e_1_2_6_40_2","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.4049\/jimmunol.141.7.2335","article-title":"IL\u20104 is required to generate and sustain in vivo IgE responses","volume":"141","author":"Finkelman FD","year":"1988","journal-title":"J Immunol"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.18.6880"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1995.tb06639.x"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(95)00041-Y"},{"key":"e_1_2_6_44_2","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.4049\/jimmunol.151.10.5563","article-title":"In vivo characterization of the anti inflammatory effects of cyclosporin A on human basophils","volume":"151","author":"Casolaro V","year":"1993","journal-title":"J Immunol"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1159\/000237015"},{"key":"e_1_2_6_46_2","first-page":"1145","article-title":"Inhaled nedocromil sodium reduces histamine release from isolated large airway segments of asthmatic subjects in vivo","volume":"6","author":"Maxwell DL","year":"1993","journal-title":"Eur Respir J"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(93)81704-4"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.21.12398"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01778336"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01796261"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.38.22467"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.160.4.1170"},{"key":"e_1_2_6_53_2","first-page":"543","article-title":"New therapeutic approaches in atopic dermatitis","volume":"11","author":"Cooper KD","year":"1993","journal-title":"Clin Rev Allergy"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.153.2.8564089"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2222.1998.00240.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2222.1998.00240.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1365-2222.1998.00240.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2222.1998.00240.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T10:09:07Z","timestamp":1694426947000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2222.1998.00240.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1998,3]]}},"alternative-id":["10.1046\/j.1365-2222.1998.00240.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2222.1998.00240.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,3]]}}}